Abstract-Tripartite motif (TRIM) 8 functions as an E3 ubiquitin ligase, interacting with and ubiquitinating diverse substrates, and is implicated in various pathological processes. However, the function of TRIM8 in the heart remains largely uncharacterized. This study aims to explore the role of TRIM8 in the development of pathological cardiac hypertrophy. Mice and isolated neonatal rat cardiomyocytes overexpressing or lacking TRIM8 were examined in several experiments. The effect of aortic banding-induced cardiac hypertrophy was analyzed by echocardiographic, pathological and molecular analyses. Our results indicated that the TRIM8 overexpression in hearts exacerbated the cardiac hypertrophy triggered by aortic banding. In contrast, the development of pathological cardiac hypertrophy was profoundly blocked in TRIM8-deficient hearts. Mechanistically, our study suggests that TRIM8 may elicit cardiodetrimental effects by promoting the activation of transforming growth factor β-activated kinase 1 (TAK1)-p38/JNK signaling pathways. Similar results were observed in cultured neonatal rat cardiomyocytes treated with angiotensin II. The rescue experiments using the TAK1-specific inhibitor 5z-7-ox confirmed the requirement of TAK1 activation in TRIM8-mediated pathological cardiac hypertrophy. Furthermore, TRIM8 contributed to TAK1 activation by binding to and promoting TAK1 ubiquitination. In conclusion, our study demonstrates that TRIM8 plays a deleterious role in pressure overload-induced cardiac hypertrophy by accelerating the activation of TAK1-dependent signaling pathways. (Hypertension. 2017;69:249-258.
H earts respond to cardiac stress or injury with adaptive hypertrophic growth, which is characterized by increases in cardiac weight and cardiomyocyte volume. 1 However, long periods of overload stimulation induce the transition from compensated hypertrophy to decompensated hypertrophy, which is characterized by ventricular dilation and contractile dysfunction; these events eventually progress to heart failure (HF). 2 The development of cardiac hypertrophy and HF is a complicated process that involves a broad range of cardiomyocyte alterations, such as abnormal intracellular calcium homeostasis, metabolic disorders, excessive oxidative stress, and fetal gene expression. Also involved are changes in the extracellular matrix, including fibrosis and angiogenesis. 3, 4 On hypertrophic stresses, signaling pathways, as pivotal regulators of cardiac hypertrophy, initiate and coordinate various pathophysiological processes. 5, 6 Therefore, molecules that can modulate the activity of specific signaling pathways could be the promising therapeutic targets for preventing cardiac hypertrophy.
The tripartite motif (TRIM) 8 sequence was identified by Vincent et al 7 in chromosomal region 10q24.3. The gene encodes a protein that is ubiquitously expressed in diverse tissues; however, levels seem to be much higher in the heart. 8 TRIM8 belongs to a designated tripartite motif subfamily defined by the presence of a RING-finger, 1 or 2 B-box domains, and a coiled-coil motif. Furthermore, there is an additional proline-rich domain in its C-terminal region of TRIM8, which is essential for its nuclear localization without stresses. 8 Based on its RING-finger domain structure, it was concluded that TRIM8 is an E3 ubiquitin ligase that regulates the activity of specific signaling pathways. TRIM8 has been determined to be involved in several pathological processes, ranging from oncogenesis to anti-infection response. Initially, TRIM8 was considered to be a tumor suppressor February 2017 because the encoding gene is located in a region showing frequent alternation in various cancers. 7, 9 Accordingly, TRIM8 was found to enhance the sensitivity of chemoresistant renal cell carcinoma to chemotherapy by displacing MDM2 from p53 and preventing p53 degradation. 10 In contrast, other evidence indicated that TRIM8 contributes to carcinogenesis by positively regulating the JAK/STAT3 (Janus kinase/signal transducer and activator of transcription 3) and nuclear factor kappa B (NF-κB) signaling pathways. 11, 12 In addition to its contrasting roles in the regulation of oncogenesis, further studies have suggested a critical role of TRIM8 in the immune response. Specifically, TRIM8 reverses SOCS-1-mediated suppression of interferon-γ signaling and targets transforming growth factor β-activated kinase 1 (TAK1) for K63-linked polyubiquitination, promoting tumor necrosis factor-α-and interleukin-1β-triggered NF-κB activation. 13, 14 Although the involvements of SOCS-1, TAK1, the proinflammatory cytokines, and NF-κB in pathological cardiac hypertrophy have been well-established, 3, [15] [16] [17] the role of TRIM8 in this complicated process remains to be determined.
In the present study, we observed elevated expression of TRIM8 in myocardium from both patients with dilated cardiomyopathy and mice subjected to AB. Consistent with the in vivo data, TRIM8 is upregulated in cultured neonatal rat cardiomyocytes (NRCMs) treated with angiotensin II (Ang II). Subsequently, mice and NRCMs with TRIM8 deletion or overexpression were generated to explore the effects of TRIM8 on cardiac hypertrophy and its underlying mechanisms. To our best knowledge, we provide the first evidence that TRIM8 deficiency prevents pathological cardiac hypertrophy on stresses, whereas TRIM8 overexpression has the opposite effects. Mechanistically, we discovered that TRIM8 interacts with TAK1 to facilitate the latter's phosphorylation. Collectively, our data suggest that TRIM8 may potentiate the development of pathological cardiac hypertrophy by enhancing the activation of TAK1-dependent signaling pathways.
Materials and Methods
An expanded Materials and Methods section is available in the onlineonly Data Supplement, which includes reagents, human ventricular samples, cultured neonatal rat cardiomyocytes and recombinant adenoviral vectors, 18, 19 animals and aortic banding, 20, 21 echocardiography measurements, histological analysis, quantitative real-time polymerase chain reaction and Western blotting, plasmid constructs, and IP assays. 22, 23 The data are displayed as the mean±SD. Comparisons between 2 groups were analyzed using the unpaired Student t test, whereas comparisons among >2 groups were performed by 1-way ANOVA followed by the Bonferroni test post hoc test (assuming equal variances) or Tamhane T2 test post hoc test (without the assumption of equal variances). All of the statistical analyses were performed with SPSS software, version 19.0, and a value of P<0.05 was considered statistically significant.
Results

TRIM8 Expression Is Increased in Failing Human Hearts and Hypertrophied Mouse Hearts
To explore the effects of TRIM8 on the development of cardiac hypertrophy and HF, we first investigated whether expression levels of TRIM8 were varied in samples from patients with end-stage HF. Western blots showed that TRIM8 expression in failing human hearts dramatically upregulated compared with normal donor hearts. Concomitant with the increase of TRIM8 expression, elevated levels of cardiac hypertrophic markers, including atrial natriuretic peptide and β-myosin heavy chain, were observed ( Figure 1A and 1B) . In addition, as evidenced by the elevated levels of atrial natriuretic peptide and β-myosin heavy chain, TRIM8 expression increased progressively in hypertrophied mouse hearts on AB. More importantly, we observed the elevation of TRIM8 expression at an earlier time point than atrial natriuretic peptide ( Figure 1C and 1D) . Consistent with the results from the in vivo experiments, in vitro analyses revealed that TRIM8 levels were increased by ≈31% and 41% in cultured NRCMs incubated with Ang II (1 μmol/L) for 24 and 48 hours, respectively, compared with the PBS-treated controls ( Figure S1A in the online-only Data Supplement). Further experiments showed that TRIM8 is majorly expressed in the nucleus of hearts without stresses. In contrast, TRIM8 was located primarily in the cytoplasm of hearts after AB surgery ( Figure S1B and S1C). Taken together, these data suggest that TRIM8 may play a critical role in the development of pathological cardiac hypertrophy.
TRIM8 Deficiency Ameliorates Pressure OverloadInduced Cardiac Hypertrophy and HF
To investigate the role of TRIM8 in modulating cardiac hypertrophy and HF, we generated TRIM8 global knockout mice ( Figure S2A through S2E) . The TRIM8-knockout mice were healthy, fertile, and there were no apparent abnormalities in their cardiac morphology or function compared with wild-type (WT) mice at baseline (data not shown). Increased ratios of heart weight/body weight (HW/BW) and tibia length, as well as an increase in both the gross size of the heart and cardiomyocyte cross-sectional area, were observed in WT mice four weeks after AB. In contrast, this increase was profoundly blunted in the hearts of TRIM8-knockout mice ( Figure S2F ; Figure 2A and 2B). We then evaluated the cardiac fibrosis in response to chronic pressure overload. Hearts sections were stained with picrosirius red to assess the extent of fibrosis, which was quantified as the left ventricular (LV) collagen volume. TRIM8-knockout mice exhibited a reduced extent of cardiac interstitial and perivascular fibrosis compared with WT mice four weeks after AB (Figure 2A and 2C). In parallel with alleviated cardiac hypertrophy and fibrosis, TRIM8-knockout mice displayed less ventricular dilation than WT mice, as evidenced by a decrease in the LV end-systolic dimension and LV end-diastolic dimension ( Figure S2G ). Moreover, 4 weeks of AB resulted in a significant reduction of fractional shortening, which is a critical hallmark of cardiac contractility in WT mice compared with TRIM8-knockout mice ( Figure S2G ). Furthermore, TRIM8 deficiency prevented the development of pressure overloadinduced pulmonary congestion, as indicated by reduced ratios of lung weight to body weight (LW/BW; Figure S2F ). Accordingly, the mRNA levels of hypertrophic and fibrotic markers were dramatically elevated in WT hearts on AB. In contrast, these mRNAs were increased to a less pronounced extent in TRIM8-knockout mice on AB ( Figure S2H ). Altogether, these data suggest that TRIM8 deficiency does not induce pathological alterations at baseline, but remarkably blunts the susceptibility of the heart to pressure overload-induced cardiac hypertrophy and HF.
TRIM8 Overexpression Exaggerates Cardiac Hypertrophy and HF Induced by Pressure Overload
To evaluate whether the overexpression of TRIM8 in hearts would aggravate pressure overload-induced cardiac hypertrophy and HF, we generated transgenic mice with cardiac-specific TRIM8 overexpression ( Figure S3A ). Four independent lines of TRIM8-transgenic mice (transgenic 1, transgenic 2, transgenic 3, and transgenic 4) were established and confirmed by Western blots ( Figure S3B and S3C). Importantly, all of the lines of TRIM8-transgenic mice were healthy, fertile, and had no obvious abnormalities in their cardiac morphology or function compared with their CAG-CAT-TRIM8/α-myosin heavy chain-MerCreMer littermates without tamoxifen administration (CTMC) at baseline (data not shown). Subsequently, the transgenic 4 line with comparable elevation of TRIM8 expression as that observed in AB-induced hypertrophied heart was selected for further experiments. Four weeks after AB, cardiac-specific TRIM8 overexpression significantly promoted AB-induced cardiac hypertrophy, as evidenced by increase in the HW/BW and HW/tibia length ratios, the gross size of the heart, and the cardiomyocyte cross-sectional area compared with CTMC mice ( Figure S3D ; Figure 3A and 3B). Accordingly, the upregulation of cardiac fibrosis was observed in TRIM8-transgenic hearts but to a less pronounced extent in CTMC hearts four weeks after AB ( Figure 3A and 3C). Concomitant with progressed cardiac hypertrophy and fibrosis, TRIM8-transgenic mice displayed a more exaggerated ventricular dilation than the controls, as indicated by elevated LV end-systolic dimension and LV end-diastolic dimension values ( Figure S3E ). In addition, fractional shortening determined by echocardiographic measurements was significantly deteriorated in TRIM8-transgenic mice compared with CTMC mice, implying poorer cardiac contractility ( Figure S3E ). These changes were accompanied by accelerated pulmonary congestion, which is an indicator of HF, as evidenced by elevated LW/ BW ratios in TRIM8-transgenic mice ( Figure S3D ). TRIM8-transgenic hearts consistently showed higher mRNA levels of hypertrophic markers and collagen synthesis indices compared with the CTMC littermates ( Figure S3F ). Collectively, these results support the hypothesis that TRIM8 contributes to the progression of cardiac hypertrophy and HF.
TRIM8 Exacerbates Ang II-Induced Cardiomyocyte Hypertrophy In Vitro
Considering that the in vivo results may be affected by components of cardiac cells besides cardiomyocytes, we further determined whether TRIM8 directly modulates isolated cardiomyocytes on prohypertrophic stimuli. NRCMs were generated that expressed either decreased or increased levels of TRIM8 by infection with AdshTRIM8 (adenoviral short hairpin TRIM8) or AdTRIM8 (adenoviral TRIM8), respectively ( Figure S4A ). We then treated the cardiomyocytes with either Ang II (1 μmol/L) or PBS for 48 hours. This treatment was followed by immunostaining with α-actinin to evaluate the cell surface area. There were no significant differences in cardiomyocyte morphology or cell surface area between PBS-treated groups. However, AdshTRIM8 infection markedly attenuated Ang II-mediated cardiomyocyte hypertrophy compared with AdshRNA-infected controls. This conclusion was reached based on decreased cell surface area in AdshTRIM8-infected NRCMs subjected to Ang II treatment ( Figure 4A and 4B). Conversely, compared with the AdGFP (adenoviral green fluorescent protein)-infected controls, TRIM8 overexpression dramatically exaggerated Ang II-mediated cardiomyocyte hypertrophy ( Figure 4A and 4C) . Similarly, on Ang II administration, TRIM8-deficient cardiomyocytes expressed lower mRNA levels of hypertrophic markers, including atrial natriuretic peptide, brain natriuretic peptide, and β-myosin heavy chain ( Figure S4B ), whereas TRIM8-overexpressing cardiomyocytes exhibited the opposite phenotype ( Figure S4C ). These in vitro data suggest that TRIM8 promotes pathological cardiac hypertrophy, at least partly, by modulating cardiomyocytes directly.
TRIM8 Enhances Hypertrophic Stresses-Induced Activation of P38 and JNK1/2 Signaling Pathways
To delineate the underlying mechanisms by which TRIM8 elicits prohypertrophic effect, we next investigated the state of the mitogen-activated protein kinases, including MEK1/2, ERK1/2, P38, and JNK1/2. These factors are well-accepted critical players in the development of pathological cardiac hypertrophy and HF. [24] [25] [26] In response to pressure overload, neither the absence nor the overexpression of TRIM8 in mouse hearts altered the activity of MEK1/2 and ERK1/2. Conversely, the AB-induced activation of P38 and JNK1/2 was significantly attenuated in TRIM8-knockout hearts but enhanced in TRIM8-transgenic hearts ( Figure 5A and 5B). However, the total expression of mitogen-activated protein kinase signaling molecules was not altered among the tested groups. In accordance with in vivo results, compared with controls, TRIM8-deficient cardiomyocytes blunted the activation of P38 and JNK1/2 ( Figure S5A ). In contrast, overexpression of TRIM8 in cardiomyocytes resulted in the opposite phenotype ( Figure S5B ). These results indicated that TRIM8 may exert prohypertrophic actions via promoting P38 and JNK1/2 signaling.
TRIM8 Interacts With and Activates TAK1 on Hypertrophic Stresses
The activation of TAK1, an upstream activator of both P38 and JNK1/2, was reported to be involved in pathological cardiac hypertrophy and to be regulated by TRIM8 in innate immune responses.
14, 16 We, therefore, hypothesized that TRIM8 may modulate the activation of P38 and JNK1/2 in a TAK1-dependent manner. Western blot assays were used to assess the expression and activation of TAK1 in hypertrophied models. At baseline, TAK1 phosphorylation levels were not affected by TRIM8 expression alternation. Notably, AB-triggered TAK1 phosphorylation was markedly ameliorated in TRIM8-knockout hearts, whereas cardiac-specific overexpression of TRIM8 increased TAK1 phosphorylation on pressure overload ( Figure 6A and 6B). Nevertheless, there was no obvious difference in the total expression levels of TAK1 among the tested groups. In parallel, we observed similar results in vitro experiments using NRCMs infected with AdshTRIM8 or AdTRIM8 ( Figure S6A and S6B) . Furthermore, coimmunoprecipitation experiments in human embryonic kidney 293T (HEK293T) cells transfected with HA (YPYDVPDYA)-tagged TRIM8 and FLAG (DYKDDDDK)-tagged TAK1 were performed to test whether TRIM8 activated TAK1 directly or indirectly. Our results revealed a physical interaction between TRIM8 and TAK1 ( Figure 6C ). Additional coimmunoprecipitation experiments were performed to investigate endogenous protein interactions in NRCMs. We observed that TRIM8 interacts with TAK1 weakly at baseline (PBS), but this interaction was significantly enhanced by Ang II administration ( Figure  S6C ). We next sought to explore the regions within TRIM8 and TAK1 that were responsible for their association. To this end, we constructed several deletion mutants of TRIM8 and TAK1 ( Figure 6D ). Our results excluded the requirement of carboxy-terminal (TRIM8 183-551aa) in TRIM8 for TAK1 binding, as evidenced by the association of TAK1 with TRIM8 1-182aa but not with TRIM8 183-551aa. In addition, the aminoterminal of TRIM8 (TRIM8 1-58aa) was insufficient for the association of TRIM8 with TAK1, whereas the internal regions of TRIM8 (TRIM8 59-182aa) could bind to TAK1 ( Figure 6E ). Furthermore, we found that amino acids 301 to 480 of TAK1 were required for this association ( Figure 6F ). Collectively, these results suggest that TRIM8-mediated exacerbation of pathological cardiac hypertrophy may be associated with potentiated TAK1 activation.
TAK1-Dependent Signaling Pathways Are Essential for the TRIM8-Mediated Prohypertrophic Response
The TAK1-specific inhibitor 5z-7-ox was utilized to test the hypothesis that TRIM8 exerts prohypertrophic action by activating TAK1-dependent signaling pathways. Specifically, the inhibitor was used to determine whether the exaggerated hypertrophic response in TRIM8-transgenic mice could be rescued by blocking TAK1-dependent signaling. Compared with DMSO-treated controls, the AB-induced phosphorylation of TAK1-dependent signaling components in hearts was largely diminished by 5z-7-ox treatment ( Figure S7A ). As predicted, 5z-7-ox reversed the worsened hypertrophic response in TRIM8-overexpressing hearts. These results were evidenced by the following observations in AB-subjected TRIM8-transgenic mice that were treated with 5z-7-ox compared to control mice treated with DMSO: (1) decrease in the HW/BW, HW/tibia length, and LW/BW ratios ( Figure S7B ), as well as the gross size of the heart ( Figure S7C ) and the cardiomyocyte cross-sectional area ( Figure S7D) ; (2) alleviated cardiac fibrosis ( Figure S7C and S7E); and (3) ameliorated cardiac dysfunction ( Figure S7F ). These data further validated that the prohypertrophic effect of TRIM8 is largely mediated by promoting the activation of TAK1-dependent signaling pathways.
TRIM8-Mediated TAK1 Ubiquitination Is Required for Cardiac Hypertrophy
Considering that TRIM8 was reported to play as an E3 ubiquitin ligase and promote phosphorylation of TAK1 by targeting TAK1 for polyubiquitination, 14 we hypothesized that TRIM8-mediated TAK1 ubiquitination is required for cardiac hypertrophy. To this end, we performed ubiquitination assays and confirmed the positive regulatory of TRIM8 on TAK1 polyubiquitination ( Figure S8A ). As the RINGfinger domain of TRIM8 is presumed to be responsible for its ubiquitin ligase activity, we generated a TRIM8 mutant without RING-finger domain (TRIM8-ΔRING, TRIM8 59-551aa) to transfect HEK293T cells and found that TRIM8-ΔRING lost the ability to promote TAK1 ubiquitination ( Figure S8B ). Then, we took advantage of TRIM8-ΔRING to test whether the ubiquitin ligase activity of TRIM8 is essential for its prohypertrophic role. Interestingly, TRIM8-ΔRING overexpression abolished the phosphorylation of TAK1 and subsequent hypertrophic response in NRCMs on Ang II administration ( Figure S8C through S8E) . Taken together, our results suggest that the E3 ligase activity of Figure 6 . Tripartite motif (TRIM) 8 interacts with and activates transforming growth factor β-activated kinase 1 (TAK1) on hypertrophic stresses. A, Representative Western blots (top) and quantitative results (bottom) of total and phosphorylated levels of TAK1 in wild-type (WT) and TRIM8-knockout (KO) hearts 4 wk after sham or aortic banding (AB) surgery (n=4 mice per experimental group; *P<0.05 vs WT/sham; #P<0.05 vs WT/AB). B, Representative Western blots (top) and quantitative results (bottom) of total and phosphorylated levels of TAK1 in CTMC and TRIM8-transgenic (TG) hearts 4 wk after the sham or aortic banding (AB) surgery (n=4 mice per experimental group; *P<0.05 vs CTMC/sham; #P<0.05 vs CTMC/AB). C, Top: Representative Western blots performed with a HA or FLAG antibody after co-IP of TRIM8 from human embryonic kidney 293T (HEK293T) lysates using a HA antibody. Bottom, Representative Western blots performed with a HA or FLAG antibody after co-IP of TAK1 from HEK293T lysates using a FLAG antibody. D, Schematic representation of the full-length and truncated forms of TRIM8 (left) and the full-length and truncated forms of TAK1 (right) that were used to determine the domains that mediate their interaction. E, Representative Western blots performed using a HA or FLAG antibody after co-IP of the full-length and truncated forms of TRIM8 from HEK293T lysates using the FLAG antibody. F, Representative Western blots performed using a HA or FLAG antibody after co-IP of the full-length and truncated forms of TAK1 from HEK293T lysates using the FLAG antibody.
TRIM8 is necessary for TAK1 activation and subsequent cardiac hypertrophy.
Discussion
In the current study, we discovered that TRIM8 expression was increased in human failing hearts, hypertrophied mouse hearts, and Ang II-treated cardiomyocytes. In addition, genetic approaches were utilized to explore the potential effects of TRIM8 on pathological cardiac hypertrophy. Our results indicate that TRIM8 functions as a positive regulator of cardiac hypertrophy on pathological stimulation.
TRIM8 was reported to interact with and regulate multiple substrates, including SOCS1, 13 TAK1, 14 PIAS3, 11 and P53, 10 thereby implicating it in various pathological processes, ranging from antiviral defense to cancer development. Intriguingly, a growing number of studies have supported the involvement of immunity and tumor regulators in modulating cardiac hypertrophy, [27] [28] [29] implying the possible involvement of TRIM8 in cardiac hypertrophy. In the present study, a progressive increase in TRIM8 expression during the development of pathological cardiac hypertrophy further raises the possibility that TRIM8 may play a critical role in these complicated processes. However, the mechanisms underlying the elevation of TRIM8 expression on hypertrophic stresses were not examined in our study. Previous studies demonstrated that TRIM8 expression could be manipulated by multiple mechanisms. In murine B lymphoid M12 cells and HeLa cells, TRIM8 mRNA can be induced by interferon-γ. 13 In addition, Caratozzolo et al 10 reported that p53 promotes TRIM8 expression under stress and that TRIM8 in turn stabilizes p53, forming a positive feedback loop. Given that augmented interferon-γ and p53 protein levels were detected in both Ang II-treated cardiomyocytes and hypertrophied mouse hearts, 27, 30, 31 we speculate that interferon-γ and p53 might be responsible for the increased expression of TRIM8 on hypertrophic stimulation. However, additional studies are required to elucidate the precise mechanisms involved in regulating TRIM8 expression in hearts.
As TRIM8 expression was increased in human failing hearts and hypertrophied mouse hearts, we speculated that the upregulation of TRIM8 may contribute to the progression of cardiac hypertrophy under pathological stresses. In support of this hypothesis, global TRIM8 deficiency protected against hypertrophic growth, adverse remodeling, and subsequent HF induced by pressure overload. Considering that a global deletion of TRIM8 may affect components of cardiac cells other than cardiomyocytes, we confirmed our results by examining mice that specifically overexpressed TRIM8 in cardiomyocytes and genetically modified NRCMs. Consistent with the findings observed in TRIM8-deficient mice, the pressure overload-induced hypertrophic response was markedly exacerbated in TRIM8-transgenic mice. Furthermore, similar results were observed using in vitro gain-and loss-of-function experiment in NRCMs. Therefore, our results provided convincing evidence that TRIM8 plays a detrimental role in pathological cardiac hypertrophy.
It will be more important to understand how TRIM8 facilitates the progression of pathological cardiac hypertrophy.
Given that mitogen-activated protein kinase signaling pathways, including ERK1/2, p38, and JNK1/2, have been shown to play important roles in cardiac hypertrophy, [24] [25] [26] Western blots were performed to analyze whether TRIM8 regulates mitogen-activated protein kinase signaling pathways. Our study demonstrated that the exaggerated hypertrophic response in TRIM8-transgenic hearts was accompanied by enhanced activation of P38 and JNK1/2. In contrast, TRIM8-knockout mice displayed the opposite phenotype. TAK1, a vital upstream activator of JNK1/2 and P38, was reported to participate in the development of pathological cardiac hypertrophy. 16 Then, the status of TAK1 after AB was therefore examined in both TRIM8-deficient and TRIM8-overexpressing hearts. As predicted, the results revealed that TAK1 phosphorylation was significantly blocked in TRIM8-knockout hearts subjected to pressure overload, whereas TRIM8 overexpression accelerated AB-induced TAK1 phosphorylation. In addition, the rescue experiments confirmed the requirement of TAK1 activation for the TRIM8-mediated prohypertrophic function. These findings are in agreement with previous reports that the activation of TAK1 is essential and sufficient to provoke pathological cardiac hypertrophy. 16, 32, 33 Coimmunoprecipitation experiments were performed to determine whether TRIM8 regulates the activity of TAK1 directly or indirectly. In cardiomyocytes, we observed that TRIM8 could interact with TAK1 weakly without stresses, but this interaction was significantly enhanced by Ang II administration. This phenomenon could be explained by the fact that TRIM8 translocates from nucleus to cytoplasm in response to hypertrophic stimuli. Additional experiments provided the first evidence that TRIM8 amino acids 59 to 182 and TAK1 amino acids 301 to 480 are responsible for their association. More importantly, we demonstrated that the ubiquitin ligase activity of TRIM8 is required for the phosphorylation of TAK1 and prohypertrophic effect of TRIM8 in cardiomyocytes. These data are consistent with previous results presented by Li et al 14 who discovered that TRIM8 interacts with and promotes tumor necrosis factor-α-and interleukin-1β-induced phosphorylation of TAK1 by targeting TAK1 for K63-linked polyubiquitination. However, Li et al 14 reported that TRIM8-transgenic-mediated TAK1 activation contributes to the phosphorylation of JNK, but not of P38, in THP1 and U937 cells.
14 Although the exact mechanisms are elusive, there is a potential reason for this discrepancy. The specificity and magnitude of TAK1 activity is regulated by many mechanisms, including distinct scaffold proteins, docking site motifs, etc. 34, 35 Therefore, the effect of activated TAK1 on the P38 and JNK pathway depends on specific cellular circumstance and upstreams stimuli. Taken together, our findings suggest that the nuclear localization of TRIM8 prevents it from binding TAK1 under basal condition, whereas hypertrophic stimuli promote TRIM8 translocation to the cytoplasm where it serves as a ubiquitin ligase to associate with TAK1, resulting in the ubiquitination and phosphorylation of TAK1 and subsequent cardiac hypertrophy.
In conclusion, the upregulation of TRIM8 contributes to adverse remodeling of the hearts on hypertrophic stresses. Furthermore, our study provides compelling evidence to support the hypothesis that TRIM8 exaggerates the development of cardiac hypertrophy, fibrosis, and subsequent HF by enhancing TAK1-dependent signaling. Thus, our results suggest that targeting TRIM8 could potentially be a therapeutic strategy for pathological cardiac hypertrophy and HF.
Perspectives
The current study is the first to demonstrate that TRIM8 promotes pathological cardiac hypertrophy by enhancing TAK1-dependent signaling. These findings broaden our understanding of the molecular mechanisms of cardiac hypertrophy and suggest that targeting TRIM8 could potentially be a therapeutic strategy for pathological cardiac hypertrophy.
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